Cargando…
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Centers for Disease Control and Prevention
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721148/ https://www.ncbi.nlm.nih.gov/pubmed/36454688 http://dx.doi.org/10.15585/mmwr.mm7148e1 |
| _version_ | 1784843706759643136 |
|---|---|
| author | Link-Gelles, Ruth Ciesla, Allison Avrich Fleming-Dutra, Katherine E. Smith, Zachary R. Britton, Amadea Wiegand, Ryan E. Miller, Joseph D. Accorsi, Emma K. Schrag, Stephanie J. Verani, Jennifer R. Shang, Nong Derado, Gordana Pilishvili, Tamara |
| author_facet | Link-Gelles, Ruth Ciesla, Allison Avrich Fleming-Dutra, Katherine E. Smith, Zachary R. Britton, Amadea Wiegand, Ryan E. Miller, Joseph D. Accorsi, Emma K. Schrag, Stephanie J. Verani, Jennifer R. Shang, Nong Derado, Gordana Pilishvili, Tamara |
| author_sort | Link-Gelles, Ruth |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9721148 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Centers for Disease Control and Prevention |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97211482022-12-13 Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 Link-Gelles, Ruth Ciesla, Allison Avrich Fleming-Dutra, Katherine E. Smith, Zachary R. Britton, Amadea Wiegand, Ryan E. Miller, Joseph D. Accorsi, Emma K. Schrag, Stephanie J. Verani, Jennifer R. Shang, Nong Derado, Gordana Pilishvili, Tamara MMWR Morb Mortal Wkly Rep Full Report Centers for Disease Control and Prevention 2022-12-02 /pmc/articles/PMC9721148/ /pubmed/36454688 http://dx.doi.org/10.15585/mmwr.mm7148e1 Text en https://creativecommons.org/publicdomain/zero/1.0/All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated. |
| spellingShingle | Full Report Link-Gelles, Ruth Ciesla, Allison Avrich Fleming-Dutra, Katherine E. Smith, Zachary R. Britton, Amadea Wiegand, Ryan E. Miller, Joseph D. Accorsi, Emma K. Schrag, Stephanie J. Verani, Jennifer R. Shang, Nong Derado, Gordana Pilishvili, Tamara Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 |
| title | Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 |
| title_full | Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 |
| title_fullStr | Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 |
| title_full_unstemmed | Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 |
| title_short | Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 |
| title_sort | effectiveness of bivalent mrna vaccines in preventing symptomatic sars-cov-2 infection — increasing community access to testing program, united states, september–november 2022 |
| topic | Full Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721148/ https://www.ncbi.nlm.nih.gov/pubmed/36454688 http://dx.doi.org/10.15585/mmwr.mm7148e1 |
| work_keys_str_mv | AT linkgellesruth effectivenessofbivalentmrnavaccinesinpreventingsymptomaticsarscov2infectionincreasingcommunityaccesstotestingprogramunitedstatesseptembernovember2022 AT cieslaallisonavrich effectivenessofbivalentmrnavaccinesinpreventingsymptomaticsarscov2infectionincreasingcommunityaccesstotestingprogramunitedstatesseptembernovember2022 AT flemingdutrakatherinee effectivenessofbivalentmrnavaccinesinpreventingsymptomaticsarscov2infectionincreasingcommunityaccesstotestingprogramunitedstatesseptembernovember2022 AT smithzacharyr effectivenessofbivalentmrnavaccinesinpreventingsymptomaticsarscov2infectionincreasingcommunityaccesstotestingprogramunitedstatesseptembernovember2022 AT brittonamadea effectivenessofbivalentmrnavaccinesinpreventingsymptomaticsarscov2infectionincreasingcommunityaccesstotestingprogramunitedstatesseptembernovember2022 AT wiegandryane effectivenessofbivalentmrnavaccinesinpreventingsymptomaticsarscov2infectionincreasingcommunityaccesstotestingprogramunitedstatesseptembernovember2022 AT millerjosephd effectivenessofbivalentmrnavaccinesinpreventingsymptomaticsarscov2infectionincreasingcommunityaccesstotestingprogramunitedstatesseptembernovember2022 AT accorsiemmak effectivenessofbivalentmrnavaccinesinpreventingsymptomaticsarscov2infectionincreasingcommunityaccesstotestingprogramunitedstatesseptembernovember2022 AT schragstephaniej effectivenessofbivalentmrnavaccinesinpreventingsymptomaticsarscov2infectionincreasingcommunityaccesstotestingprogramunitedstatesseptembernovember2022 AT veranijenniferr effectivenessofbivalentmrnavaccinesinpreventingsymptomaticsarscov2infectionincreasingcommunityaccesstotestingprogramunitedstatesseptembernovember2022 AT shangnong effectivenessofbivalentmrnavaccinesinpreventingsymptomaticsarscov2infectionincreasingcommunityaccesstotestingprogramunitedstatesseptembernovember2022 AT deradogordana effectivenessofbivalentmrnavaccinesinpreventingsymptomaticsarscov2infectionincreasingcommunityaccesstotestingprogramunitedstatesseptembernovember2022 AT pilishvilitamara effectivenessofbivalentmrnavaccinesinpreventingsymptomaticsarscov2infectionincreasingcommunityaccesstotestingprogramunitedstatesseptembernovember2022 |